Skip to content
  • Saturday, 12 September 2026
  • 6:32 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Apr 20, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Apr 12, 2026 0

Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Apr 2, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Mar 25, 2026 0

Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Mar 18, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…

Read More
Molecular Switch Discovery at Weill Cornell Medicine Enhances Blood Stem Cell Regeneration and Bone Marrow Transplant EfficacyScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921Solar-Powered Innovation: Turning the Global Plastic Crisis into a Sustainable Energy RevolutionBeyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy PorustobartScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ